STRO Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of -255.85%. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Sutro Biopharma, Inc. has a consensus price target of $22.43, signalling upside risk potential of 151.16%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -71.19%. Given that Sutro Biopharma, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Sutro Biopharma, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Sutro Biopharma, Inc. has a beta of 1.615, which suggesting that the stock is 61.536% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Sutro Biopharma, Inc.'s net income of -$56.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 4.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 2.29x versus 5.73x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of --. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat Palatin Technologies's return on equity of --.

Sutro Biopharma, Inc. has a consensus price target of $22.43, signalling upside risk potential of 151.16%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Sutro Biopharma, Inc., analysts believe Palatin Technologies is more attractive than Sutro Biopharma, Inc..

Sutro Biopharma, Inc. has a beta of 1.615, which suggesting that the stock is 61.536% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are larger than Palatin Technologies quarterly revenues of --. Sutro Biopharma, Inc.'s net income of -$56.9M is higher than Palatin Technologies's net income of --. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 2.29x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Syndax Pharmaceuticals, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of -132.36%. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat Syndax Pharmaceuticals, Inc.'s return on equity of -136.36%.

Sutro Biopharma, Inc. has a consensus price target of $22.43, signalling upside risk potential of 151.16%. On the other hand Syndax Pharmaceuticals, Inc. has an analysts' consensus of $39.31 which suggests that it could grow by 94.3%. Given that Sutro Biopharma, Inc. has higher upside potential than Syndax Pharmaceuticals, Inc., analysts believe Sutro Biopharma, Inc. is more attractive than Syndax Pharmaceuticals, Inc..

Sutro Biopharma, Inc. has a beta of 1.615, which suggesting that the stock is 61.536% more volatile than S&P 500. In comparison Syndax Pharmaceuticals, Inc. has a beta of 0.476, suggesting its less volatile than the S&P 500 by 52.361%.

Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Syndax Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. Syndax Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are smaller than Syndax Pharmaceuticals, Inc. quarterly revenues of $45.9M. Sutro Biopharma, Inc.'s net income of -$56.9M is higher than Syndax Pharmaceuticals, Inc.'s net income of -$60.7M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while Syndax Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 2.29x versus 15.64x for Syndax Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics, Inc. has a net margin of -586.58% compared to Sutro Biopharma, Inc.'s net margin of --. Sutro Biopharma, Inc.'s return on equity of -10195.04% beat Theriva Biologics, Inc.'s return on equity of -171.04%.

Sutro Biopharma, Inc. has a consensus price target of $22.43, signalling upside risk potential of 151.16%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3897.72%. Given that Theriva Biologics, Inc. has higher upside potential than Sutro Biopharma, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Sutro Biopharma, Inc..

Sutro Biopharma, Inc. has a beta of 1.615, which suggesting that the stock is 61.536% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.

Sutro Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sutro Biopharma, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.

Sutro Biopharma, Inc. quarterly revenues are $9.7M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Sutro Biopharma, Inc.'s net income of -$56.9M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Sutro Biopharma, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sutro Biopharma, Inc. is 2.29x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.